NEURALPLEXER

Owners

Goods & Services

Drug discovery services; platform as a service (PAAS) featuring a computer software platform for using artificial intelligence for collecting, analyzing, interpreting and reporting data and information in the field of drug design and development; platform as a service (PAAS) featuring a computer software platform for using artificial intelligence and machine learning for molecular docking; platform as a service (PAAS) featuring a computer software platform for using artificial intelligence for biomolecular structure prediction; platform as a service (PAAS) featuring a computer software platform for using artificial intelligence in the field of drug design and development; research and development of new therapeutic targets for others; scientific and medical research; artificial intelligence as a service (AIAAS) services featuring software using artificial intelligence (AI) for collecting, analyzing, interpreting and reporting data and information in the field of drug design and development; artificial intelligence as a service (AIAAS) services featuring software using artificial intelligence (AI) for molecular docking; artificial intelligence as a service (AIAAS) services featuring software using artificial intelligence (AI) for biomolecular structure prediction; artificial intelligence as a service (AIAAS) services featuring software using artificial intelligence (AI) for automated machine learning in the field of drug design and development; advanced product research in the field of artificial intelligence (AI); research and development of pharmaceutical drugs to treat diseases utilizing a proprietary drug discovery platform; medical and scientific research services in the field of machine learning models for biomolecular structure prediction